scholarly journals The Role of Targeted Therapy in Metastatic Renal Cell Carcinoma

2007 ◽  
Vol 7 ◽  
pp. 800-807 ◽  
Author(s):  
Jaya Unnithan ◽  
Brian I. Rini
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mammalian Target Of Rapamycin ◽  
Growth Factor Receptor ◽  
Vascular Tumor ◽  
Disease Biology ◽  
Endothelial Growth Factor

Renal cell carcinoma (RCC) is a highly vascular tumor in which a growing understanding of disease biology has been translated into clinically active systemic therapies. The most clinically developed targeted therapies in advanced RCC are those that target the vascular endothelial growth factor (VEGF) ligand or receptor (VEGFR) and therapy directed against the mammalian target of rapamycin (mTOR). Sutent and sorafenib are orally available inhibitors of the VEGFR and platelet derived growth factor receptor (PDGFR). Temsirolimus is an mTOR inhibitor that leads to G1cell cycle arrest and may affect VEGF production. This article briefly describes the biological pathways involved in the development of RCC and the results of clinical trials using targeted therapy in metastatic RCC.

scholarly journals The efficacy of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma exhibiting primary resistance to front-line targeted therapy or immunotherapy

2020 ◽  
Vol 16 (3) ◽  
pp. 53-61
Author(s):  
L. Hamieh ◽  
R. L. Beck ◽  
V. H. Le ◽  
J. J. Hsieh
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Targeted Therapy ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Vascular Endothelial ◽  
Front Line ◽  
Primary Resistance ◽  
Endothelial Growth Factor

Введение. Пациенты с первично резистентным метастатическим почечно-клеточным раком (мПКР) обычно имеют плохой прогноз заболевания с плохим ответом на последующее лечение. Несмотря на то что в настоящее время существует несколько одобренных схем 2-й линии терапии мПКР, вопрос выбора наиболее эффективной среди них остается открытым.Материалы и методы. Мы идентифицировали 7 пациентов со светлоклеточным вариантом мПКР и первичной резистентностью к ингибиторам тирозинкиназы (ИТК) рецепторов сосудистого эндотелиального фактора роста (vascular endothelial growth factor, VEGF) или к комбинированной терапии ингибиторами иммунных контрольных точек (ИИКТ). Пациенты получали ленватиниб (многоцелевой ИТК) в комбинации с эверолимусом (ингибитор мишени рапамицина млекопитающих). Всем участникам исследования ранее было выполнено лечение: 2 пациента получали ИТК, 3 пациента — ИИКТ, 2 пациента — ИТК и ИИКТ. Мы проанализировали клинические характеристики пациентов, их молекулярно-генетические профили, продолжительность лечения, его результаты, а также нежелательные явления.Результаты. Медиана времени до прогрессирования на фоне предшествующей терапии составила 1,5 мес. Пациенты получали комбинацию ленватиниб + эверолимус в рамках терапии 2-й (n = 4) или 3-й (n = 3) линии. У 3 пациентов достигнут частичный ответ, у 3 больных зафиксирована стабилизация заболевания. Длительность наблюдения составила ≥ 17 мес. Выживаемость без прогрессирования — 3—15мес, общая выживаемость — 4—17 мес.Заключение. Представленные в настоящей статье 7 случаев демонстрируют реальные результаты применения комбинации ленватиниб + эверолимус у пациентов со светлоклеточным мПКР и первичной резистентностью к ИТК VEGF или к комбинированной терапии ИИКТ.

Treatment Strategies in Metastatic Renal Cell Carcinoma

2010 ◽  
Vol 06 (02) ◽  
pp. 41
Author(s):  
Alain Ravaud ◽  
Jean Christophe Bernhard ◽  
Marine Gross-Goupil ◽  
◽  
◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Mammalian Target Of Rapamycin ◽  
Treatment Strategies ◽  
Growth Factor Receptor ◽  
Clinical Effects ◽  
Improved Outcomes ◽  
Endothelial Growth Factor

Metastatic renal cell carcinoma (mRCC) is associated with a poor clinical outcome. Until recently, treatment recommendations were limited to immunotherapy and nephrectomy; however, an increased understanding of the molecular biology of RCC has led to the advent of targeted therapies directed against vascular endothelial growth factor/receptor (VEGF/VEGFR) or the mammalian target of rapamycin (mTOR) pathways, both major mediators of tumour growth and progression. These targeted agents have significantly improved outcomes in patients with mRCC, revolutionising treatment. These treatments have overlaps and important distinctions in terms of clinical effects, toxicity and patient populations in which they have been investigated. Concerns in terms of the appropriate sequencing of these agents, their combined use and their role in the context of nephrectomy have emerged as clinically relevant and are being actively investigated.

scholarly journals Pleiotropic Stromal Effects of Vascular Endothelial Growth Factor Receptor 2 Antibody Therapy in Renal Cell Carcinoma Models

Neoplasia ◽  
2011 ◽  
Vol 13 (1) ◽  
pp. 49-59 ◽  
Author(s):  
Inga J. Duignan ◽  
Erik Corcoran ◽  
Anthony Pennello ◽  
Mary Jane Plym ◽  
Michael Amatulli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Antibody Therapy ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor

scholarly journals Case: Secondary polycythemia due to pazopanib in patients with metastatic renal cell carcinoma

2017 ◽  
Vol 11 (11) ◽  
pp. E449-50 ◽  
Author(s):  
Nedal Bukhari ◽  
Eric Winquist
Keyword(s):  
Renal Cell Carcinoma ◽  
Growth Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Growth Factor Receptor ◽  
Cell Receptor ◽  
Renal Neoplasm ◽  
Vascular Endothelial ◽  
Cell Renal Cell Carcinoma ◽  
Endothelial Growth Factor

Clear-cell renal cell carcinoma (RCC) is the most common primary malignant renal neoplasm. Up to 30% of patients have metastatic disease at the time of initial diagnosis.1 Small molecule inhibitors of vascular endothelial growth factor receptor tyrosine kinase (VEGFR TKIs) are used as first-line treatment for most patients with incurable RCC. Pazopanib is a TKI inhibiting VEGFR,1-3 as well as plateletderived growth factor receptors (PDGFRs) α and β and stem cell receptor c-kit. The most common side effects of pazopanib are diarrhea, hypertension, changes in hair colour, anorexia, nausea, and vomiting. Severe hepatic toxicity is the adverse effect of greatest concern,but is uncommon. Myelosuppressive effects are also noted, such as anemia, thrombocytopenia, and leukopenia, and are presumably mediated through c-kit inhibition. Erythrocytosis is a wellrecognized paraneoplastic syndrome associated with RCC; however, erythrocytosis due to pazopanib therapy has only recently been described. We report two cases and review of the literature related to this phenomenon.

Sign in / Sign up

Export Citation Format

Share Document